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SUMMARY
Objective: To evaluate whether immunohistochemical marker studies performed on core needle 
biopsy (CNB) specimens accurately reflect the marker status of the tumor obtained from final 
surgical specimen. Methods: This was a retrospective study that used the database of the Divi-
sion of Mastology of the Hospital das Clínicas, São Paulo, Brazil. Sixty-nine patients submitted to 
ultrasound-guided CNB diagnosed with breast cancer were retrospectively analyzed. Immunohis-
tochemistry (IHC) on core biopsy specimens was compared to that of excisional biopsy regarding 
estrogen receptor (ER), progesterone receptor (PR), human epidermal gowth factor receptor 2 gene 
(HER2), p53, and Ki67. The analysis of the concordance between CNB and surgical biopsy was 
performed using the kappa (k) coefficient (95% CI). Results: A perfect concordance between the 
labeling in the surgical specimens and the preoperative biopsies in p53 (k = 1.0; 95% CI: 0.76-1.0) 
was identified. There was an almost perfect concordance for ER (k = 0.89; 95% CI: 0.65-1.0) and a 
substantial concordance for PR (k = 0.70; 95% CI: 0.46-0.93). HER2 (k = 0.61; 95% CI: 0.38-0.84) 
and Ki-67 (k = 0.74; 95% CI: 0.58-0.98) obtained a substantial concordance this analysis. Conclu-
sion: The results of this study indicate that the immunohistochemical analysis of ER, PR, Ki-67, 
and p53 from core biopsy specimens provided results that accurately reflect the marker status of 
the tumor. The concordance rate of HER2 was less consistent; although it produced substantial 
concordance, values were very close to moderate concordance.
Keywords: Breast neoplasms; core needle biopsy; hormone receptor; HER2/neu; Ki-67; immuno-
istochemical.
RESUMO
Análise das taxas de concordância entre a biópsia com agulha grossa 
e a excisão cirúrgica em pacientes com câncer de mama
Objetivo: Avaliar se a análise dos marcadores imunoistoquímicos obtidos por meio de espé-
cimes de core biopsy (CB) refletem com precisão o perfil dos marcadores tumorais obtidos por 
biópsia cirúrgica excisional (BCE). Métodos: Estudo retrospectivo usando dados da Divisão 
de Mastologia do Hospital das Clínicas de São Paulo. Sessenta e nove pacientes submetidas à 
CB guiada por ultrassom com diagnóstico de câncer de mama foram analisadas retrospectiva-
mente. O exame imunoistoquímico dos espécimes de CB foram comparados com aquele obti-
do a partir da BCE em relação ao receptor de estrogênio (RE), receptor de progesterona (RP), 
human epidermal gowth factor receptor 2 gene (HER2), p53 e Ki-67. A análise de concordância 
entre a CB e a BCE foram realizados usando o coeficiente de kappa (k) (IC 95%). Resultados: 
A concordância perfeita entre a BCE e a CB do p53 (k = 1,0; IC 95%: 0,76-1,0) foi identificada. A 
concordância foi quase perfeita para o RE (k = 0,89; IC 95%: 0,65-1,0) e concordância substancial 
foi identificada para o RP (= 0,70; IC 95%: 0,46-0,93). O HER2 (k = 0,61; IC 95%: 0,38-0,84) e Ki-67 
(k = 0,74; IC 95%: 0,58-0,98) obtiveram uma concordância substancial nesta análise. Conclusão: os 
resultados deste estudo indicam que a análise imunoistoquímica do RE, RP, Ki-67 e p53 a partir dos 
espécimes de CB fornecem resultados que refletem com precisão o perfil dos marcadores do tumor. 
O HER2 foi menos consistente, porque apesar de ter produzido uma concordância substancial, os 
valores foram muito próximos da concordância moderada.
Unitermos: Neoplasia de mama; biópsia por agulha; receptor hormonal; HER2; Ki-67; HER2.
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INTRODUCTION
Breast cancer is a molecularly heterogeneous disease. 
Markers such as estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal gowth factor recep-
tor 2 gene (HER2) are used for prognostic evaluation and 
to stratify patients for appropriate target therapies. Core 
needle biopsy (CNB) specimens provides adequately sized 
samples permitting a histological diagnosis, allowing, for 
example, the differentiation between in situ and invasive 
carcinoma1,2. CNB samples can also be utilized in immu-
nohistochemical (IHC) assays of hormone receptor and 
other prognostic tumor markers3-14. The ER, PR, HER2, 
and Ki-67 status of these samples provide valuable prog-
nostic information and predict tumor response to neoad-
juvant and adjuvant chemotherapy7,15.
Estrogen and progesterone hormone receptor status 
tests are typically performed on all invasive breast cancers10. 
Patients who have ER-positive and PR-positive tumors 
tend to have a better prognosis for disease-free survival and 
overall survival than those with ER-negative or PR-nega-
tive tumors. They are also much more likely to respond to 
endocrine therapy. HER2 overexpression is associated with 
certain clinical outcomes, such as higher risk of recurrence 
and mortality, relative resistance to endocrine therapy, 
and apparent lesser benefit from certain chemotherapeu-
tic regimens16.  Ki-67 is a cancer antigen that is found in 
growing, dividing cells, but is absent in the resting phase of 
cell growth. This characteristic makes Ki-67 a good tumor 
marker. The researchers agreed that high levels of Ki-67 in-
dicate an aggressive tumor and predict a poor prognosis16.
In some breast cancer patients, especially those treated 
with preoperative chemotherapy or neoadjuvant endo-
crine therapy, the CNB specimen may be the only pretreat-
ment tissue sample available for assays of prognostic and 
predictive markers17. In theory, cytotoxic chemotherapy 
may result in sufficient tumor regression to alter histo-
logical, hormonal, and proliferative markers7,16. Tumor 
ablation may completely modify the status of prognostic 
markers, and IHC analysis of ER, PR, HER2 expression, 
and Ki-67 index may be analogous to molecular analysis 
by microarray18,19.
The diagnoses obtained from the pathologic examina-
tion of CNB and surgically excised specimens have been 
shown to be similar, with a sensitivity for non-palpable 
tumors controlled radiologically of 90% to 95% for the de-
tection of breast cancer20. CNB specimens accurately sam-
ple a very small target without false-positive diagnosis20,21.
Several previous studies have shown that, in general, 
the histologic features of carcinomas in core biopsy speci-
mens accurately reflect those seen in subsequently excised 
tumors6,20. In one study, the nuclear grade and combined 
grade of the CNB samples agreed to the respective grade 
of the corresponding excised specimens in approximately 
75% of patients22. In contrast, there have been few stud-
ies assessing the correlation between ER, PR, p53, HER2 
staining, and Ki-67 index in preoperative CNB and final 
surgical specimens. 
METHODS
This is a retrospective cross-sectional study that included 
CNB samples obtained before surgery and excised breast 
tumor specimens from 69 patients with breast cancer, not 
selected consecutively, in the Department of Mastology of 
the Hospital das Clínicas in São Paulo. Data were collected 
between May through October 2011. Tumor size was not 
used as a factor in selection of cases. The study protocol 
was approved by the ethics in research committee of the 
institution. None of the patients had received chemother-
apy, radiotherapy, or hormone therapy between CNB and 
surgical excision. CNB samples were obtained under real 
time ultrasound guidance, using a linear transducer with 
a frequency of at least 7.5 MHz. The tissue samples were 
obtained using an automated biopsy gun with a 14-gauge 
needle (Bard Magnum – C.R. Bard, Covington, Ga) while 
monitoring the needle’s passage within the lesion to assure 
adequate sampling. 
Paraffin sections of the core biopsy specimens and 
corresponding resected tumors were incubated with an-
tibodies to ER (clone 1D5, DAKO), PR receptor (clone 
PgR 636, DAKO), HER2 (polyclonal, DAKO), p53 (clone 
DO-7, DAKO), and Ki-67 (clone MIB1, Immunotech). 
Blots were developed using the streptavidin-biotin-per-
oxidase method for HER2 or the avidin-streptavidin-
biotin peroxidase method for the other antibodies. Stain-
ing was estimated semiquantitatively, based on staining 
intensity and on the percentage of positive cells. ER and 
PR staining were considered positive when > 10% of the 
tumor cells showed distinct nuclear staining. For HER2, 
immunohistochemical staining scores of 0 and +1 were 
considered negative and scores of +3 were considered 
positive; scores of +2 were considered inconclusive, and 
these samples were excluded from analysis. The Ki-67 in-
dex measured the percentage of invasive cancer cell nu-
clei that were positive, with cut-offs for analysis of < 10%, 
10-25%, 25-50%, and > 50%. 
The concordance or discordance between core biopsy 
and surgical biopsy specimens was analyzed by determin-
ing the kappa coefficient (95% CI) using the kappa (k) test 
of concordance. Concordances of 0.21-0.40, 0.40-0.60, 
0.60-0.80, 0.80-1.00, and 1.00 were defined as fair, moder-
ate, substantial, almost perfect, and perfect, respectively23. 
RESULTS
Sixty-nine patients with a breast CNB diagnosed as carcino-
ma followed by surgical excision of the tumor were assessed. 
An average of five core samples per lesion (range: 3–8) was 
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obtained, with each specimen consisting of core tissues suit-
able for standard histologic analysis. Mean patient age was 
52 years (range: 30-76 years), and tumor size ranged from 
10 to 80 mm. Of the 69 patients, 42 (60.8%) were diagnosed 
with invasive ductal carcinoma, eight (11.7%) with inva-
sive ductal carcinoma and ductal carcinoma in situ (DCIS), 
17 (24.7%) with invasive lobular carcinoma, one (1.4%) 
with intra-cystic papillary carcinoma, and one (1.4%) with 
primary squamous cell carcinoma of the breast. 
The histologic types determined on core biopsy corre-
lated with the types determined on surgical biopsy. When 
the concordance between the CNB and surgical biopsy 
specimens for ER, PR, Ki-67, p53, and HER2 was assayed, 
concordance was observed in specimens from 66 (95%), 
60 (87%), 57 (82%), 69 (100%), and 54 (78%) patients, 
respectively. Using kappa statistics, the concordance be-
tween the preoperative biopsy and surgical specimens was 
perfect (k = 1.0) for p53, almost perfect for ER (k = 0.89), 
and substantial for Ki-67 index (k = 0.74), PR (k = 0.70), 
and HER2 (k = 0.61) (Table 1).
DISCUSSION
Breast cancer is a heterogeneous disease, and gene expres-
sion studies have identified molecularly distinct subtypes 
with prognostic implications across multiple treatment 
settings. The IHC evaluation of ER, PR, Ki-67 index, and 
HER2 has been considered accurate in identifying molecu-
lar subtypes of breast cancer19. Four subtypes (luminal A, 
luminal B, HER2, and triple negative) have been found use-
ful in defining different prognostic subgroups with different 
responses to adjuvant treatment18,19. Luminal A tumors are 
those with hormone-receptor-positive (either estrogen and/
or progesterone-positive) and are HER2-negative; lumi-
nal B tumors are hormone-receptor-positive (either estro-
gen and/or progesterone-positive) and are HER2-positive; 
HER2 over-expressing tumors are hormone-receptor-nega-
tive and are HER2-positive; and triple-negative tumors are 
hormone-receptor-negative and are HER2-negative18,19. The 
use of neoadjuvant chemotherapy for locally advanced tu-
mors has increased the importance of a correct preoperative 
evaluation of the proliferative activity and immunohisto-
chemical markers of the tumor7. Pilot studies have shown 
that neoadjuvant treatment with trastuzumab combined 
with chemotherapy induces marked clinical and pathologic 
responses in patients with tumors overexpressing HER224. 
In these patients, CNB samples are assayed to diagnose pa-
tients before the start of chemotherapy or monoclonal an-
tibody treatment, since treatment may alter the tumor ex-
pression of biologic markers, such as ER, PR, Ki-67, p53, 
and HER225.
The concordance rates for CNB and surgically excised 
specimens have been found to range from 81.3% to 100% for 
ER, from 42% to 89% for PR, from 86% to 100% for p53, and 
from 86.9% to 100% for HER23-14. In agreement with previ-
ous findings8,21, concordances between CNB and surgical 
samples were observed for all of tumor markers. At least 
three core samples were needed for the reliable assessment 
of HER2 after adding chromogenic in situ hybridization 
(CISH), and more than three core samples were needed for 
PR, possibly due to tissue heterogeneity8. ER sensitivity was 
found to be lower (95%) even in multiple core samples, sug-
gesting that when CNB samples are negative for ER, the sur-
gical samples should be further assayed8. Interestingly, when 
CNB and surgical samples were discordant, the core biopsy 
samples consistently showed enhanced receptor stain inten-
sity compared with the surgical specimens26.
An IHC study of 56 patients reported concordance 
rates of 100% for HER2 and p536. In two other studies, 
HER2 showed relatively higher concordance rates be-
tween core and resected samples when assayed by fluores-
cence in situ hybridization (FISH) in relation to IHC4,14. 
Similar to the present findings, the concordance rates were 
95% for ER, 89% for PR and 86% for p5314. A study using 
FISH in 336 patients showed a concordance rate of 98.8% 
for HER212. In another study, involving 353 patients, the 
concordance rates of ER and PR by IHC were 81.3% and 
92.9%, respectively, and the concordance rate of HER2 by 
FISH was 89.3%13. A similar study in 100 patients reported 
IHC concordance rates of 95.8% for ER and 90.3% for PR, 
and a FISH concordance rate of 86.9% for HER210. 
The concordance rate found in the present study was 
higher for ER than for PR, perhaps due to the relatively ho-
mogeneous distribution of ER throughout these tumors. 
The heterogeneity of ER expression in tumor cell popula-
tions may have implications for analytic cell selection and 
for prognosis in patients with ER-positive carcinomas3.
Immunohistochemical marker Concordance (kappa)* 95% CI p
Estrogen receptor 0.89 (0.65-1.0) < 0.001
Progesterone receptor 0.70 (0.46-0.93) < 0.001
HER2 0.61 (0.38-0.84) < 0.001
Ki-67 0.74 (0.58-0.89) < 0.001
p53 1.0 (0.76-1.0) < 0.001
*0.21-0.40 = fair; 0.41-0.60 = moderate; 0.61-0.80 = substantial; 0.81-1.00 = almost perfect; and 1.0 = perfect concordance.
Table 1 – Values of the concordance coefﬁcient kappa for the analyzed immunohistochemical markers
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The HER2 results of this study were less consistent. The 
relative discordance may be due to differences in method-
ology, because HER2 expression was analyzed by IHC, 
whereas other studies have analyzed HER2 expression 
by FISH. FISH assays of HER2 overexpression have been 
shown to be more sensitive than IHC assays27.
The present results indicate that the dichotomously 
scored markers ER and PR can be accurately evaluated 
in core biopsy specimens. Previous studies have reported 
that, if core biopsy specimens are ER negative, surgical 
specimens should be analyzed. The HER2 status of a core 
biopsy specimen may be more reliable if assayed by FISH 
or CISH rather than by IHC.
Few studies have assayed differences in Ki-67 index be-
tween CNB and excisional biopsy specimens. In one study, 
the expression of ER, PR, HER2, p53 and Ki-67 correlated 
in core biopsy and surgically resected tumor samples from 
25 patients receiving neoadjuvant chemotherapy, with 
no significant differences in expression patterns from a 
group of 30 patients who did not receive neoadjuvant che-
motherapy15. An analysis of ER and PR status and Ki-67 
score in CNB specimens before and after treatment with 
letrozole in 63 postmenopausal women with breast cancer 
showed that letrozole treatment decreases the expression 
of Ki-67 and PR28.
This study has several potential limitations. First, it was 
retrospective in design, and therapy or lack of therapy was 
not determined on a randomized basis. Any discordance 
between CNB and surgically resected specimens may be 
due to various factors, including tumor sampling, techni-
cal preparation of the immunohistochemical stain, fixa-
tion time, or inter-observer variability. Another possible 
limitation was that HER2 status was analyzed by IHC, 
not by FISH or CISH, which are considered the standard 
methods for assessing HER2 status. In addition, patients 
with IHC HER2 +2 were excluded because of the lack of 
FISH or CISH results, which may have caused some selec-
tion bias. The discordance may also have been related to 
tumor size diversity of the selected patients, as well as the 
number of samples obtained by CNB.
CONCLUSIONS
These results indicate that immunohistochemical assays 
of ER, PR, and p53 in CNB samples accurately reflect the 
marker status of the tumor. The concordances for HER2 
status were less consistent, suggesting that FISH or CISH 
assays of core biopsy specimens may be more specific in 
predicting prognosis and selecting treatment. The Ki-67 
index results should be interpreted with caution to distin-
guish the luminal A and B breast cancer subtypes. 
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